

# DEPARTMENT OF

HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.



Stacie Weeks, JD MPH Administrator

## **Drug Utilization Review**

# **Board Meeting Minutes**

Date of Meeting: Thursday, April 18, 2024

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record		Notes	
1) Call to Order and Roll Call	It was announced the meeting is being record	DHCFP Staff Present were as follows:		
	Chairperson Jennifer Wheeler called the meeting to order at 1:03 p.m. on January 18, 2024. Chairperson Wheeler took the roll.			<ul> <li>Lither, Gabriel, Senior Deputy Attorney General (SDAG)</li> <li>Duncan, Keiko, PharmD, Medicaid Pharmacy Director</li> <li>Clemons, Roshanda, MD, Medicaid Medical Director</li> </ul>
		Present	Absent	Flowers, Ellen, Social Services Program
	• Jennifer Wheeler, Pharm.D., Chair	$\boxtimes$		Specialist II
	Netochi Adeolokun, Pharm.D., Vice-Chair	$\boxtimes$		
	Crystal Castaneda, MD		$\boxtimes$	Magellan Rx Staff Present were as
	• Jessica Cate, Pharm.D.		$\boxtimes$	follows:
	• Dave England, Pharm.D.	$\boxtimes$		Mishra, Raj, Pharm.D., Clinical Account
	Brain Le, DO	$\boxtimes$		Manager
	• Jim Tran, Pharm.D.			<ul> <li>Brittany Deoliveira, Pharm.D., Clinical Account Manager</li> <li>Martinez, Chris, Sr. Business Analyst</li> <li>Killpack, Andy, Pharm.D., Director, Specialty Clinical Solutions</li> </ul>

2) General Public Comment	Telephonic and web comment was called for, an were opened.	nd the	e phon	e lines	<ul> <li>Managed Care Organization representatives present were as follows: <ul> <li>Lim, Luke, Pharm.D., Anthem</li> <li>Bitton, Ryan, Pharm.D., Health Plan of Nevada</li> <li>Marquez, Joy, Pharm.D., Silver Summit Health Plan</li> <li>Tran, Jimmy, Pharm.D., Molina Healthcare</li> </ul> </li> <li>The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</li> </ul>
3) Administrative	No public comment was provided.				
a) For Possible Action: Review and Approve Meeting Minutes from January 18, 2024.	Vice-Chair Netochi Adeolokun moved to approve presented, and Board Member Dave England se A vote was taken, and the results were as follow attendance (in favor, against, and abstentions v	cond vs froi	ed the m men	motion. nbers in	
	• Jennifer Wheeler, Pharm.D., Chair	Yes ⊠ □ □ ⊠	No	Abst. □ □ □ □	

	• Jim Tran, Pharm.D.	
b) Status Update by DHCFP	Medicaid Pharmacy Director, Dr. Keiko Duncan provided an announcement.	
	<ul> <li>I did want to call out that we do have two open positions on this</li> </ul>	
	DUR board. So, we are recruiting for that. If you or anybody you	
	know are interested, we do have the instructions posted on our	
	DHCFP website. You're welcome to email your CV to us at our	
	email at RxInfo@dhcfp.nv.gov.	
4) Clinical Presentations		
a. For Possible Action:		
Discussion and possible		
adoption of prior		
authorization criteria and/or		
quantity limits for <b>CASGEVY.</b> i) Public comment on	Telephonic and web comment was called for, and the phone lines	
proposed clinical prior	were opened.	
authorization criteria.	were opened.	
	Public comment was provided by Georgia May Glass.	
	Public comment was provided by Felton White.	
	Public comment was provided by Dawn Bey.	
ii) Presentation of	Dr. Raj Mishra provided the clinical background and indications for	
utilization and clinical	Casgevy.	
information.	Dr. Mishra reviewed the proposed criteria presented in the binder	
	and discussed the utilization of Casgevy.	
	and discussed the demization of cuspery.	
	• Dr. Luke Lim with Anthem, approved of the proposed criteria and	
	utilization presented.	
	• Dr. Ryan Bitton with Health Plan of Nevada, approved of the	
	proposed criteria and utilization presented.	

<ul> <li>iii) Discussion by Board and review of utilization data.</li> <li>iv) Proposed adoption of</li> </ul>	<ul> <li>Dr. Joy Marquez with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> <li>Chairperson Wheeler asked for comments from the Board Members.</li> <li>No comments were made.</li> <li>Board Member England moved to approve the criteria as presented</li> </ul>				
updated prior authorization criteria.	Vice-Chair Adeolokun seconded the motion. A vote was taken, and the results were as follo	by Magellan with the change of bullet number 3 to 4 instead of 8 and /ice-Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
	<ul> <li>Jennifer Wheeler, Pharm.D., Chair</li> <li>Netochi Adeolokun, Pharm.D., Vice-Chair</li> <li>Crystal Castaneda, MD</li> <li>Jessica Cate, Pharm.D.</li> <li>Dave England, Pharm.D.</li> <li>Brain Le, DO</li> <li>Jim Tran, Pharm.D.</li> </ul>	Yes ⊠ □ □ ⊠ ⊠ ⊠ ∞ ∞ ∞	No	Abst.	
<ul> <li>b) For Possible Action:</li> <li>Discussion and possible adoption of prior authorization criteria and/or quantity limits for</li> <li>LYFGENIA.</li> </ul>					
<ul> <li><u>Public comment</u> on proposed clinical prior authorization criteria.</li> </ul>	Telephonic and web comment was called for, a were opened. Public comment was provided by Jason Balla.	and the	e phon	e lines	
	Public comment was provided by Georgia May	Glass			

ii)	Presentation of utilization and clinical information.	Dr. Mishra provided the clinical background ar Lyfgenia.				
		Dr. Mishra reviewed the proposed criteria pres and discussed the utilization for Lyfgenia.				
		<ul> <li>Dr. Lim with Anthem, approved of the projutilization presented.</li> <li>Dr. Bitton with Health Plan of Nevada, app</li> </ul>				
		<ul><li>criteria and utilization presented.</li><li>Dr. Marquez with Silver Summit Health Pla</li></ul>	n, app			
		<ul> <li>proposed criteria and utilization presented</li> <li>Dr. Tran with Molina Healthcare, approved criteria and utilization presented.</li> </ul>		e propo	osed	
iii)	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments fror Comments were made by Board Member Engl		Board I	Nembers.	
iv)	Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the by Magellan with the change of bullet point nu will be for 4 instead of 8 and Vice-Chair Adeolo motion. (The Board decided to go back to Casg the same change.)	criteri imber okun se	4. The econde	change ed the	
		A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
		<ul> <li>Jennifer Wheeler, Pharm.D., Chair</li> <li>Netochi Adeolokun, Pharm.D., Vice-Chair</li> <li>Crystal Castanada, MD</li> </ul>	Yes ⊠	No	Abst.	
		<ul><li>Crystal Castaneda, MD</li><li>Jessica Cate, Pharm.D.</li></ul>			$\boxtimes$	

	Dave England, Pharm.D.
	Brain Le, DO     X
	• Jim Tran, Pharm.D.
c) For Possible Action:	
Discussion and possible	
adoption of prior	
authorization criteria and/or	
quantity limits for WAINUA.	
i) <u>Public comment</u> on	Telephonic and web comment was called for, and the phone lines
proposed clinical prior	were opened.
authorization criteria.	
	No public comment was provided.
ii) Presentation of	Dr. Mishra provided the clinical background and indications for
utilization and clinical	Wainua.
information.	
	Dr. Mishra reviewed the proposed criteria presented in the binder
	and discussed the utilization for Wainua.
	• Dr. Lim with Anthem, approved of the proposed criteria and
	utilization presented.
	<ul> <li>Dr. Bitton with Health Plan of Nevada, approved of the proposed</li> </ul>
	criteria and utilization presented.
	Dr. Marquez with Silver Summit Health Plan, approved of the
	proposed criteria and utilization presented.
	<ul> <li>Dr. Tran with Molina Healthcare, approved of the proposed</li> </ul>
	criteria and utilization presented.
iii) Discussion by Board and	Chairperson Wheeler asked for comments from the Board Members.
review of utilization data.	
	Comment was made by Board Member Brain Le.

iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as Magellan, and Board Member England seconded the m A vote was taken, and the results were as follows from attendance (in favor, against, and abstentions where ap	otion.			
	YesYesJennifer Wheeler, Pharm.D., ChairImage: ChairNetochi Adeolokun, Pharm.D., Vice-ChairImage: Crystal Castaneda, MDCrystal Castaneda, MDImage: Crystal Castaneda, MDJessica Cate, Pharm.D.Image: Crystal Castaneda, Pharm.D.Dave England, Pharm.D.Image: Crystal Castaneda, Pharm.D.Brain Le, DOImage: Crystal Castaneda, Pharm.D.Jim Tran, Pharm.D.Image: Crystal Castaneda, Pharm.D.				
<ul> <li>d) Opioid Reports:</li> <li>i) Opioid Trends</li> <li>ii) Count of Claims</li> <li>iii) Med Trend</li> <li>iv) Top Members</li> <li>v) Top Prescribers</li> <li>vi) Top Pharmacy</li> </ul>	<ul> <li>i) Opioid Trends</li> <li>ii) Count of Claims</li> <li>iii) Med Trend</li> <li>iv) Top Members</li> <li>v) Top Prescribers</li> <li>Dr. Lim presented opioid utilization reports.</li> <li>Dr. Bitton presented opioid utilization reports.</li> <li>Dr. Marquez presented opioid utilization reports.</li> <li>Dr. Tran presented opioid utilization reports.</li> </ul>				
e) Standard DUR Reports: i. Top 10 Classes by Amount Paid ii. Top 10 Classes by Claim Count iii. Quarterly ProDUR Paid Claims Saving Report iv. Retro DUR Initiatives	<ul> <li>Dr. Mishra presented Standard DUR Reports</li> <li>Dr. Lim presented Standard DUR Reports.</li> <li>Dr. Bitton presented Standard DUR Reports</li> <li>Dr. Marquez presented Standard DUR Reports</li> <li>Dr. Tran presented Standard DUR Reports.</li> </ul>				

0			]
f)	For Possible Action:	aflibercept	
	Discussion and possible	Bavencio (avelumab)	
	adoption of prior	Beovu (brolucizumab-dbll)	
	authorization criteria and/or	bevacizumab	
	quantity limits for <b>Physician</b>	Darzalex IV (daratumumab)	
	Administered Drugs.	denosumab	
		Elaprase (idursulfase)	
		Imfinzi (durvalumab)	
		IVIG (immune globulin IV)	
		Kadcyla (ado-trastuzumab	
		emtansine)	
		Keytruda (pembrolizumab)	
		Libtayo (cemiplimab-rwlc)	
		Ocrevus (ocrelizumab	
		Opdivo (nivolumab)	
		paclitaxel albumin-bound	
		• pegfilgrastim	
		pemetrexed	
		Perjeta (pertuzumab)	
		ranibizumab	
		rituximab IV	
		• SCIG (immune globulin SQ)	
		Soliris (eculizumab)	
		Tecentrig (atezolizumab)	
		trastuzumab IV	
		Ultomiris (ravulizumab-cwvz)	
		Yervoy (ipilimumab)	
	i) <u>Public comment</u> on	Telephonic and web comment was called for, and the phone lines	
	proposed clinical prior	were opened.	
	authorization criteria.		
		No public comments were provided.	
		•	

ii) Presentation of	Dr. Killpack reviewed the proposed criteria updates presented in the	
utilization and clinical	binder for	
information.	aflibercept	
	Bavencio (avelumab)	
	Beovu (brolucizumab-dbll)	
	bevacizumab	
	Darzalex IV (daratumumab)	
	denosumab	
	Elaprase (idursulfase)	
	Imfinzi (durvalumab)	
	IVIG (immune globulin IV)	
	Kadcyla (ado-trastuzumab	
	emtansine)	
	Keytruda (pembrolizumab)	
	Libtayo (cemiplimab-rwlc)	
	Ocrevus (ocrelizumab	
	Opdivo (nivolumab)	
	paclitaxel albumin-bound	
	pegfilgrastim	
	pemetrexed	
	Perjeta (pertuzumab)	
	ranibizumab	
	rituximab IV	
	SCIG (immune globulin SQ)	
	Soliris (eculizumab)	
	Tecentriq (atezolizumab)	
	trastuzumab IV	
	Ultomiris (ravulizumab-cwvz)	
	Yervoy (ipilimumab)	
	• Dr. Lim with Anthem, approved of the proposed criteria.	
	• Dr. Bitton with Health Plan of Nevada, approved of the proposed	
	criteria.	

	<ul> <li>proposed criteria.</li> <li>Dr. Tran with Molina Healthcare, approver criteria.</li> </ul>	<ul> <li>Dr. Tran with Molina Healthcare, approved of the proposed</li> </ul>					
iii) Discussion by Board and review of utilization	Chairperson Wheeler asked for comments fro	m the	Board	Members.			
data.	No Comments were made.						
iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the c Magellan, and Board Member England second		•	•			
	A vote was taken, and the results were as follo attendance (in favor, against, and abstentions						
		Yes	No	Abst.			
	• Jennifer Wheeler, Pharm.D., Chair	$\boxtimes$					
	• Netochi Adeolokun, Pharm.D., Vice-Chair	$\boxtimes$					
	Crystal Castaneda, MD			$\boxtimes$			
	• Jessica Cate, Pharm.D.			$\boxtimes$			
	• Dave England, Pharm.D.	$\boxtimes$					
	• Brain Le, DO			$\boxtimes$			
	• Jim Tran, Pharm.D.	$\boxtimes$					
1) Closing Discussion							
a. Public Comment	Telephonic and web comment was called for, were opened.	and th	e phor	ne lines			
	Public comment was provided by Valerie Ng w	ith Le	o Phari	ma.			
<ul> <li>For Possible Action: Date and location of the next meeting.</li> </ul>	Chairperson Wheeler stated the next meeting 20, 2024.	Chairperson Wheeler stated the next meeting is scheduled for July					
	Location: Hilton Garden Inn Reno						
	Meeting adjourned at 3:13 pm						

#### Attachment A – Members of the Public in Attendance

Lisa	Pulver	Pamela	White	Madison	Zeltwanger	Sim	Wimbush	John	Meyer
Tracey	Turner	Michael	Pazirandeh	Dominic	Gaon	Olga	Triola	Georgene	Glass
Lori	Howarth	Jamie	Tobitt	Mariah	Scott	Jeny	Zendejad	Kaysen	Васа
Pam	Storey	Michele	Puyear	Mari	Nielsen	Cherryl	Cannady	Nate	Osborne
Ann	Nelson	Steven	Schultz	Deanna	Darlington	Kelly	Wright	Pam	White
Nate	Osborne	Lea	Case	Keibi	Mejia	Karen	Ou	Jason	Dougles
Dawn	Веу	Renee	Sweeney	Jennifer	Hailey	Amber	Federizo		
Lynda	Finch	Valerie	Ng	Jason	Crecco	Todd	Dickerson		
Eileen	Zmer	Sara	Stolfus	Ryan	Roa	Jeana	Colabianchi		
Cheryl	Wiley	Aaron	Girvin	Amy	Hale	Ann	Nelson		

### Attachment B – Submitted Written Comment

Cure 4 The Kids Foundation

Nevada Rare Disease Advisory Council

Bridging the Gap- Adult Sickle Cell Disease foundation of Nevada

Dreamsickle Kids Foundation

SCD Gene Therapy Access